Henry Jacob Conter

Dr. Henry Jacob Conter

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2025 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
ABAdam Brufsky
Adam Brufsky
KHKent F Hoskins
Kent F Hoskins
HCHenry Jacob Conter
Henry Jacob Conter
PKPond Kelemen
Pond Kelemen
MHMehran Habibi
Mehran Habibi
JOJoyce O’sHaughnessy
Joyce O’sHaughnessy
Background: Gene expression assays help personalize adjuvant chemotherapy decisions for hormone receptor-positive, HER2-negative (HR+HER2-) early breast cancer (EBC). The 70-gene risk of distant-recurrence signature, MammaPrint, demonstrated clinical utility in guiding chemotherapy de-escalation in genomically low risk patients in the MINDACT trial. This study evaluates MammaPrint as a continuous predictor of chemotherapy benefit in HR+HER2- EBC using real-world data (RWD) from the FLEX Registry. Methods: The study evaluated 1002 patients treated with endocrine therapy (ET) only or ET with chemotherapy (ET+CT) enrolled in FLEX (NCT03053193) with 5-year median follow-up. Propensity-score matching balanced treatment groups by menopausal status, T-stage, and nodal status. The primary endpoint was distant recurrence-free interval (DRFI). Regression and Cox proportional hazards models assessed chemotherapy benefit across MammaPrint Index (MPI) risk. Results: Most patients were postmenopausal (70.1%), node-negative (70.0%), and had grade 2 tumors (51.2%). The regression models showed that MPI strongly predicted 5-year DRFI in ET only (R2 = 0.99, P < .001) and ET + CT (R2 = 0.90, P < .001) groups, corresponding to an average absolute chemotherapy benefit of 5.6% in High 1 and 10.9% in High 2. Minimal improvement in DRFI with chemotherapy was observed for Low (1.7%) and UltraLow (<1.0%) risk groups. A multivariate Cox model with an MPI-by-treatment interaction term demonstrated that increasing MPI risk was associated with greater chemotherapy benefit on DRFI (HR = 0.15, P = .047). Chemotherapy benefit was significantly associated with premenopausal status, but not age, T-stage, nodal status, or grade. Conclusions: These RWD from the FLEX Registry demonstrate that MPI is predictive of both DRFI prognosis and chemotherapy benefit in HR+HER2- EBC. (NCT03053193)

FKFariba Kolahdooz
Fariba Kolahdooz
SJSe Lim Jang
Se Lim Jang
SDSarah Deck
Sarah Deck
DIDavid Ilkiw
David Ilkiw
GOGertrude Omoro
Gertrude Omoro
SSSangita Sharma
Sangita Sharma
Social determinants of health (SDHs) and the impact of colonization can make Canadian Arctic Indigenous communities susceptible to infectious diseases, including the coronavirus disease 2019 (COVID-19). This scoping review followed the PRISMA guidelines for scoping reviews and studied what is known about selected pandemics (COVID-19, tuberculosis, and H1N1 influenza) and SDHs (healthcare accessibility, food insecurity, mental health, cultural continuity, housing, community infrastructure, and socioeconomic status (SES)) for Canadian Arctic Indigenous communities. Original studies published in English and French up to October 2024 were located in databases (PubMed, Medline, and CINAHL), AlterNative: An International Journal of Indigenous Peoples, and through reference tracking. We included 118 studies: 6 relating to COVID-19, 5 to influenza, 5 to TB, 27 to food insecurity, 26 to healthcare access, 22 to mental health, 9 to SES, 8 to housing, 7 to cultural continuity, and 3 to community infrastructure. SDHs affecting Indigenous individuals include food insecurity, limited healthcare access, mental health challenges, low SES, suboptimal housing, and limited cultural continuity. These findings are relevant to other Arctic regions. It is crucial to understand how SDHs impact the health of Arctic communities and to utilize this information to inform policy and practice decisions for pandemic prevention, management, and treatment. Many SDHs pose challenges for preventing and managing infectious diseases.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
OROlivier Rixe
Olivier Rixe
VCVincent Castonguay
Vincent Castonguay
HCHenry Jacob Conter
Henry Jacob Conter
ECEva Chalas
Eva Chalas
PDPratibha Desai
Pratibha Desai
SFStephan Fiset
Stephan Fiset
Background: Maveropepimut-S (MVP-S) is a novel immunotherapeutic that educates a specific CD8 T cell response to the cancer antigen, survivin, to orchestrate immune-mediated elimination of survivin-expressing cancer cells. Specifically, MVP-S is a lipid-in-oil formulation of the DPX delivery platform, incorporating five survivin-specific immunogenic peptides, the innate immune stimulant, polydIdC, and a CD4 T cell helper peptide. In prior clinical studies, MVP-S and intermittent low-dose cyclophosphamide (CPA) elicited confirmed clinical responses (both partial and complete by RECISTv1.1) and induced a robust, durable survivin-specific CD8 T cell response. Moreover, the combination with pembrolizumab appeared to be well tolerated in solid tumors and lymphomas. The purpose of this phase 2 study is to explore whether this combination may be safe and effective in advanced, metastatic bladder cancer patients, both naïve to, and previously treated with, immune checkpoint inhibitors. Results: Seventeen (17) subjects were treated with the combination of MVP-S, CPA and pembrolizumab. Subjects received an average of 3 prior lines of therapy with 13/17 (76.4%) having previously received an anti-PD1/L1. Seven subjects progressed on or after anti-PD1/L1 as last line of therapy prior to entering the trial. The combination was well-tolerated, with majority of AEs being grade 1 or grade 2. Five (5) out of 17 subjects showed response: 3 subjects with PR (unconfirmed) and 2 with CR (confirmed). Three of these, including the 2 CRs, had progressed on anti-PD-1/L1. Long-term clinical benefit has been observed in several subjects (one patient is still on treatment after 17 months) and coincides with an increase in detectable survivin-specific T cells in peripheral blood. Conclusion: Preliminary data suggest that MVP-S/CPA and pembrolizumab is a well-tolerated combination and shows encouraging preliminary clinical activity in the treatment of advanced or metastatic bladder cancer patients, including patients who have progressed on prior anti-PD-1/L1 therapy. Citation Format: Olivier Rixe, Vincent Castonguay, Henry Conter, Eva Chalas, Pratibha Desai, Christian Squillante, Lisa A. MacDonald, Rebekah Conlon, Yogesh Bramhecha, Heather Hirsch, Jeremy R. Graff, Stephan Fiset. Safety, preliminary efficacy and pharmacodynamic (PD) analysis of maveropepimut-S, intermittent low-dose cyclophosphamide and pembrolizumab in patients with advanced, metastatic bladder cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT035.

1 February 2014 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
HCHenry Jacob Conter
Henry Jacob Conter
506 Background: Targeted therapy has revolutionized the treatment of mRCC. However, cost has lead to variable regional approval and funding. Can such variation in funding of established drugs impede approval of newer agents? Methods: Regulatory agency decisions regarding axitinib, the most recently approved mRCC therapy in the U.S., were reviewed. Reports from the US Food and Drug administration (FDA), the European Medicines Agency (EMA), the pan-Canadian Oncology Drug Review (pCODR), UK's National Institute for Health and Care Excellence (NICE), and the Therapeutic Goods Administration (TGA) of Australia were included. Data abstracted included the date of report publication, basis for determination of clinical efficacy, determination of cost-effectiveness, theme of stakeholder submissions prior to and after the regulatory decision, final decision, and rational for approval/rejection. Results: At the time of analysis, all agency decisions had been finalized. All of the agencies based their assessment of clinical efficacy of primarily on the same phase III clinical trial: the AXIS trial, demonstrating a progression-free survival benefit of axitinib compared to sorafenib (6.7 versus 4.7 months, p<0.001). Cost-effectiveness data was considered by NICE and pCODR, but not the FDA, the EMA, or the TGA. Axitinib was recommended received approval by the FDA, the EMA, and the TGA for use in patients with mRCC who have failed prior treatment with sunitinib or cytokines. pCODR recommended axitinib for funding in the 2nd line setting only in patients unable to tolerate everolimus. And NICE recommended against the funding of axitinib. Both dissenting organizations cited concerns with the pivotal trial’s control arm, sorafenib, not representing their regional standards of care as primary reasons for restricted access and rejection. Cost considerations were also cited as factors in the rejections. Conclusions: Differing regulatory approvals and funding worldwide are creating regional standards of care that impeding the research, development, and approval of newer agents. Divergent standards of care before and after clinical trials may restrict their external validity and applicability.

20 May 2014 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
HCHenry Jacob Conter
Henry Jacob Conter
6558 Background: Attracting private research investment to fund clinical trials in rare tumor types can be difficult. This is compounded by the inability of investors to directly invest in higher-risk trials, lack of interest in by large pharmaceutical companies, and a lack of understanding of what return on investment would be acceptable. Methods: A project finance model was created. The owner of the desired compound would license it to a special investment vehicle (SIV). The SIV would purchase the license from the holder by raising cash through a repurchase agreement with a financial institution in exchange for zero-coupon (Z-) bonds issued by the SIV. The financial institution could short sell the bonds to investors. Bond holders could hold the debt or purchase credit default swaps (CDS) to hedge risk. The Merton Model was employed to value the debt and calculate the yield per dollar of future revenue. Published clinical trial phase transition probabilities were used to estimate success. The hazard for...

20 September 2019 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
HCHenry Jacob Conter
Henry Jacob Conter
PCParneet K. Cheema
Parneet K. Cheema
6 Background: The pan-Canadian Oncology Drug Review (pCODR) provides funding recommendations to the provinces of Canada on Health Canada approved systemic therapies. Why would they recommend against funding drugs that meet regulatory standards? Methods: 136 reviews for 70 compounds were completed by pCODR from inception to January 1, 2019 were collected and data abstracted using a standardized form. For all submissions that received a negative recommendation, the Clinical Guidance Panel (CGP), Economic Guidance Panel (EGP), and Expert Review Committee (pERC) reports were examined to determine the underlying cause for rejection. Results: 32 (24%) of submissions received a negative recommendation. In all cases, this was due to concerns regarding the clinical effectiveness of the compound. Economic considerations were never cited as rational for rejection. 10 (32%) were submitted with supporting evidence from non-comparative phase 2 clinical data, and this level of evidence was cited as the basis for the recommendation. 4 (12%) supported by randomized phase 2 evidence were rejected in support of awaiting phase 3 trials in progress. 6 phase 2-based recommendations have since been overturned on re-submission with phase 3 data. Of the 18 (56%) rejected with phase 3 data, 4 had demonstrated an overall survival advantage over standard of care (range 1.5-3.8 months) that was deemed not clinically significant. 12 were rejected due to lack of confidence in surrogate end-points employed in the trial. 1 was rejected due to diminishing clinical benefit observed over time, and 1 was rejected due to data quality. The EGP calculated the median cost-effectiveness of the proposed indications to be $188,537/QALY (range 22,326-2,120,433), with a median cost increase of $47,529 (2,536-226,752) and life-years gained of 3.8 months (0.8-11). Conclusions: Regulatory approval does not translate to clinically meaningful effectiveness. Bodies that consider opportunity cost may have a higher threshold for minimum benefit than regulators.